Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001493
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
Antimetabolite Induction High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Antimetabolite Induction High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast Cance
Status:
COMPLETED
Status Verified Date:
1999-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study examines the feasibility of using gene therapy to prevent some of the toxicities of an intensive chemotherapy regimen in patients with metastatic breast cancer Patients who do not wish to participate in the gene therapy procedures will be offered identical chemotherapy on a different protocol Patients will be treated initially with chemotherapy which is active against breast cancer but which has a low potential to hurt blood-forming cells Then the patient will receive high dose chemotherapy during which time blood cells which are capable of rebuilding patients bone marrows will be removed from the patients bloodstream We will use these blood cell collections to isolate peripheral blood progenitor cells PBPCs those cells which are thought to be the forbears of all other blood cells
A portion of the PBPCs will be exposed to a disabled virus which either carries genetic material referred to as the multidrug resistance gene MDR1 The virus will transfer the MDR1 gene into a portion of the patients PBPCs The purpose of putting the MDR1 gene into the patients PBPCs is to try to make these blood cells and their offspring resistant to the toxic effects of certain types of breast cancer chemotherapy The MDR1 protein Pgp that is made from the MDR1 gene makes cells resistant to chemotherapy in laboratory systems by pumping the drug out of cells before the drug is able to kill the cell Another portion of the patients PBPCs will be exposed to a similar disabled virus carrying a different gene called the NeoR gene The NeoR gene should not change the effects of chemotherapy on blood forming cells The purpose of using the NeoR gene is that it will serve as a point of comparison to see if the presence of the MDR1 drug resistance gene really helps blood forming cells withstand subsequent chemotherapy
Patients are then treated with a very high dose of another anti-breast cancer drug one that is very toxic to bone marrow cells and patients will then receive the frozen PBPCs which contain the new genes to help them recover from the chemotherapy After recovery patients will then be treated with high doses of paclitaxel Taxol and doxorubicin Adriamycin chemotherapy Both of these drugs are very active against breast cancer and the MDR1 gene may potentially protect bone marrow cells against these drugs Samples of peripheral blood cells will be obtained before each of these doses of chemotherapy to determine whether the number of blood cells that contain the MDR1 gene in comparison to the number that contain the NeoR gene has increased in response to the chemotherapy
A portion of the PBPCs will be exposed to a disabled virus which either carries genetic material referred to as the multidrug resistance gene MDR1 The virus will transfer the MDR1 gene into a portion of the patients PBPCs The purpose of putting the MDR1 gene into the patients PBPCs is to try to make these blood cells and their offspring resistant to the toxic effects of certain types of breast cancer chemotherapy The MDR1 protein Pgp that is made from the MDR1 gene makes cells resistant to chemotherapy in laboratory systems by pumping the drug out of cells before the drug is able to kill the cell Another portion of the patients PBPCs will be exposed to a similar disabled virus carrying a different gene called the NeoR gene The NeoR gene should not change the effects of chemotherapy on blood forming cells The purpose of using the NeoR gene is that it will serve as a point of comparison to see if the presence of the MDR1 drug resistance gene really helps blood forming cells withstand subsequent chemotherapy
Patients are then treated with a very high dose of another anti-breast cancer drug one that is very toxic to bone marrow cells and patients will then receive the frozen PBPCs which contain the new genes to help them recover from the chemotherapy After recovery patients will then be treated with high doses of paclitaxel Taxol and doxorubicin Adriamycin chemotherapy Both of these drugs are very active against breast cancer and the MDR1 gene may potentially protect bone marrow cells against these drugs Samples of peripheral blood cells will be obtained before each of these doses of chemotherapy to determine whether the number of blood cells that contain the MDR1 gene in comparison to the number that contain the NeoR gene has increased in response to the chemotherapy
Detailed Description:
This pilot trial will determine whether retroviral-transduced peripheral blood progenitor cells PBPCs can be selected and expanded in vivo after non-ablative chemotherapy in patients with metastatic breast cancer It will also examine the feasibility of administering induction high-dose therapy with antimetabolites followed with consolidation using high-dose single alkylating agent therapy and finally intensification therapy with sequential cycles of very high doses of the natural product breast cancer chemotherapeutic agents paclitaxel followed by doxorubicin
Patients will receive induction therapy with antimetabolite agents methotrexate leucovorin and 5-fluorouracil for two to four cycles Patients will then receive consolidation therapy with two cycles of high-dose alkylating agents First patients will receive one cycle of high-dose cyclophosphamide administered with growth factor support PBPCs will be harvested during the recovery phase of the cyclophosphamide cycle
One-half of the cells to be reinfused will be transduced with a retroviral vector containing the gene for the multidrug resistance protein MDRI in vector G1MD and the other half will be transduced with a vector containing the neomycin resistance gene NeoR in vector G1Na40 Both of these vectors have previously been approved by the Recombinant DNA Advisory Committee for PBPC transduction in Medicine Branch protocols
The next cycle will consist of high-dose single agent thiotepa Hematopoietic stem cells mobilized and collected during the previous cyclophosphamide cycle and transduced with the retroviral vectors will be reinfused following treatment with thiotepa to augment recovery of bone marrow function After recovery intensification with natural product chemotherapy will be administered consisting of four cycles of paclitaxel given as a 24-hour infusion followed by four cycles of single agent doxorubicin Peripheral blood mononuclear cells will be monitored following each cycle of paclitaxel and doxorubicin for the presence of the MDRI and NeoR transgenes The ration of the levels of MDRI to NeoR transgenes in peripheral blood will determine whether in vivo expansion of the PBPCs containing the selectable MDRI marker has been achieved
This protocol combines several highly active chemotherapeutic agents in an attempt to improve upon response rates achieved with current combinations Patients who do not wish to participate in the gene therapy procedures will be offered identical chemotherapy in a different protocol
Patients will receive induction therapy with antimetabolite agents methotrexate leucovorin and 5-fluorouracil for two to four cycles Patients will then receive consolidation therapy with two cycles of high-dose alkylating agents First patients will receive one cycle of high-dose cyclophosphamide administered with growth factor support PBPCs will be harvested during the recovery phase of the cyclophosphamide cycle
One-half of the cells to be reinfused will be transduced with a retroviral vector containing the gene for the multidrug resistance protein MDRI in vector G1MD and the other half will be transduced with a vector containing the neomycin resistance gene NeoR in vector G1Na40 Both of these vectors have previously been approved by the Recombinant DNA Advisory Committee for PBPC transduction in Medicine Branch protocols
The next cycle will consist of high-dose single agent thiotepa Hematopoietic stem cells mobilized and collected during the previous cyclophosphamide cycle and transduced with the retroviral vectors will be reinfused following treatment with thiotepa to augment recovery of bone marrow function After recovery intensification with natural product chemotherapy will be administered consisting of four cycles of paclitaxel given as a 24-hour infusion followed by four cycles of single agent doxorubicin Peripheral blood mononuclear cells will be monitored following each cycle of paclitaxel and doxorubicin for the presence of the MDRI and NeoR transgenes The ration of the levels of MDRI to NeoR transgenes in peripheral blood will determine whether in vivo expansion of the PBPCs containing the selectable MDRI marker has been achieved
This protocol combines several highly active chemotherapeutic agents in an attempt to improve upon response rates achieved with current combinations Patients who do not wish to participate in the gene therapy procedures will be offered identical chemotherapy in a different protocol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 96-C-0007 | None | None | None |